Ascletis Pharma Inc. provided earnings guidance for the year ended December 31, 2021. For the year, The company expects to record a turnaround from a gross loss to a gross profit for the year ended December 31, 2021 and record a gross profit ranging from approximately RMB 38.5 million to RMB 40.1 million, representing an increase of approximately 264% to 270%. The Group expects to record a revenue ranging from approximately RMB 76.1 million to RMB 77.6 million for the year ended December 31, 2021, representing an increase of approximately 117% to 122%, as compared with a revenue of approximately RMB 35.0 million for the corresponding year ended December 31, 2020.